Short Interest in Pfenex Inc (PFNX) Increases By 13.4%

Pfenex Inc (NYSEAMERICAN:PFNX) was the target of a large increase in short interest during the month of December. As of December 29th, there was short interest totalling 198,379 shares, an increase of 13.4% from the December 15th total of 174,975 shares. Based on an average daily trading volume, of 721,971 shares, the days-to-cover ratio is currently 0.3 days. Approximately 1.0% of the shares of the stock are short sold.

A number of institutional investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP increased its stake in shares of Pfenex by 51.4% in the third quarter. Dimensional Fund Advisors LP now owns 304,403 shares of the biotechnology company’s stock valued at $919,000 after buying an additional 103,337 shares during the period. C WorldWide Group Holding A S increased its stake in shares of Pfenex by 10.5% in the third quarter. C WorldWide Group Holding A S now owns 271,400 shares of the biotechnology company’s stock valued at $820,000 after buying an additional 25,900 shares during the period. Sanders Morris Harris LLC increased its stake in shares of Pfenex by 33.9% in the third quarter. Sanders Morris Harris LLC now owns 998,151 shares of the biotechnology company’s stock valued at $3,015,000 after buying an additional 252,464 shares during the period. Susquehanna International Group LLP acquired a new stake in shares of Pfenex in the second quarter valued at about $272,000. Finally, Goldman Sachs Group Inc. increased its stake in shares of Pfenex by 186.0% in the second quarter. Goldman Sachs Group Inc. now owns 160,204 shares of the biotechnology company’s stock valued at $642,000 after buying an additional 104,184 shares during the period.

Shares of Pfenex (NYSEAMERICAN:PFNX) traded up $0.01 during mid-day trading on Wednesday, hitting $3.17. The company had a trading volume of 27,700 shares, compared to its average volume of 178,533. Pfenex has a twelve month low of $2.07 and a twelve month high of $9.67. The company has a market cap of $79.59, a P/E ratio of -1.78 and a beta of 3.95.

Pfenex (NYSEAMERICAN:PFNX) last posted its earnings results on Thursday, November 9th. The biotechnology company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.17. The firm had revenue of $5.02 million during the quarter, compared to the consensus estimate of $3.30 million. Pfenex had a negative return on equity of 63.57% and a negative net margin of 175.52%. The business’s quarterly revenue was down 89.7% on a year-over-year basis. During the same period last year, the company earned $1.46 earnings per share.

Several analysts recently weighed in on the company. Zacks Investment Research downgraded Pfenex from a “hold” rating to a “sell” rating in a research report on Friday, January 5th. JMP Securities dropped their price objective on Pfenex from $21.00 to $8.00 and set an “outperform” rating for the company in a research report on Friday, November 10th. Two analysts have rated the stock with a sell rating and one has assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $5.50.

TRADEMARK VIOLATION NOTICE: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/01/10/short-interest-in-pfenex-inc-pfnx-increases-by-13-4.html.

About Pfenex

Pfenex Inc is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab).

Receive News & Ratings for Pfenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply